S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
15 A.I. Trading Opportunities a Day (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
15 A.I. Trading Opportunities a Day (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
15 A.I. Trading Opportunities a Day (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
15 A.I. Trading Opportunities a Day (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
15 A.I. Trading Opportunities a Day (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
15 A.I. Trading Opportunities a Day (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
15 A.I. Trading Opportunities a Day (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
15 A.I. Trading Opportunities a Day (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
NASDAQ:NBRV

Nabriva Therapeutics (NBRV) Stock Forecast, Price & News

$1.46
-0.17 (-10.43%)
(As of 06/2/2023 ET)
Compare
Today's Range
$1.39
▼
$1.65
50-Day Range
$1.46
▼
$1.95
52-Week Range
$1.22
▼
$8.45
Volume
58,227 shs
Average Volume
21,236 shs
Market Capitalization
$46.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

NBRV stock logo

About Nabriva Therapeutics (NASDAQ:NBRV) Stock

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The company was founded in October 2005 and is headquartered in Dublin, Ireland.

Receive NBRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NBRV Stock News Headlines

June 3, 2023 | americanbankingnews.com
Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated at StockNews.com
June 1, 2023 | americanbankingnews.com
Head-To-Head Analysis: China SXT Pharmaceuticals (NASDAQ:SXTC) & Nabriva Therapeutics (NASDAQ:NBRV)
June 3, 2023 | Behind the Markets (Ad)
[BREAKING] Pentagon to Spend Billions on "Living Missile"
Air Force Magazine calls it "transformational." The Wall Street Journal calls it one of the Pentagon's "highest priorities." National Defense Magazine reports "Eye-popping budget" for it. This small company won the first contract to build them!
May 26, 2023 | americanbankingnews.com
Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated by Analysts at StockNews.com
May 26, 2023 | finance.yahoo.com
NBRV - Nabriva Therapeutics plc
May 20, 2023 | americanbankingnews.com
StockNews.com Initiates Coverage on Nabriva Therapeutics (NASDAQ:NBRV)
May 2, 2023 | americanbankingnews.com
Nabriva Therapeutics (NASDAQ:NBRV) Now Covered by Analysts at StockNews.com
February 28, 2023 | marketwatch.com
Bacterial Pneumonia Therapeutics Market Updated Report by Competitor Strategics till 2029
June 3, 2023 | Behind the Markets (Ad)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
February 25, 2023 | seekingalpha.com
NBRV Nabriva Therapeutics plc
January 6, 2023 | finance.yahoo.com
Nabriva Therapeutics Provides Corporate Update
November 28, 2022 | marketwatch.com
Nabriva Therapeutics Shares Rise 11% After Positive Xenleta Trial Data
November 28, 2022 | markets.businessinsider.com
Nabriva Adds 9% On Positive Results From Study Of Xenleta In Cystic Fibrosis
November 28, 2022 | markets.businessinsider.com
Nabriva Announces Positive Results From Phase 1 Trial Of Lefamulin In Cystic Fibrosis; Stock Up
November 28, 2022 | bizjournals.com
Nabriva stock up after firm's antibiotic shows promise as a potential cystic fibrosis treatment
November 28, 2022 | seekingalpha.com
Nabriva gains after announcing Phase 1 data for cystic fibrosis candidate
November 28, 2022 | finance.yahoo.com
Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
November 28, 2022 | finance.yahoo.com
Nabriva's stock is up after sharing antibiotic news
November 28, 2022 | finance.yahoo.com
Nabriva's antibiotic shows promise as a potential cystic fibrosis treatment
November 10, 2022 | finance.yahoo.com
Montgomery County biopharmaceutical firm reducing workforce by 40%
November 10, 2022 | technews.tmcnet.com
Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update
November 10, 2022 | finance.yahoo.com
Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update
November 7, 2022 | finance.yahoo.com
Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022
September 15, 2022 | finance.yahoo.com
Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split
September 14, 2022 | finance.yahoo.com
All You Need to Know About Nabriva Therapeutics AG (NBRV) Rating Upgrade to Buy
September 6, 2022 | finance.yahoo.com
Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 12, 2022 | marketwatch.com
Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA(R) (lefamulin) in Adult Patients with Cystic Fibrosis
See More Headlines

NBRV Price History

NBRV Company Calendar

Last Earnings
4/17/2023
Today
6/03/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NBRV
CUSIP
N/A
CIK
1641640
Web
www.nabriva.com
Phone
(531) 649-2000
Fax
610-816-6639
Employees
72
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($19.20)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-57,190,000.00
Net Margins
-148.11%
Pretax Margin
-144.78%
Return on Equity
-365.53%
Return on Assets
-135.81%

Debt

Debt-to-Equity Ratio
0.12
Current Ratio
0.85
Quick Ratio
0.52

Sales & Book Value

Annual Sales
$35.59 million
Price / Sales
1.31
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.14) per share
Price / Book
-10.43

Miscellaneous

Outstanding Shares
32,015,000
Free Float
31,493,000
Market Cap
$46.74 million
Optionable
Optionable
Beta
1.56

Key Executives

  • John Christopher NaftzgerJohn Christopher Naftzger
    CEO, Secretary & General Counsel
  • Dan Dolan
    Chief Financial Officer
  • Kim Anderson
    Investor & Media Contact

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













NBRV Stock - Frequently Asked Questions

Should I buy or sell Nabriva Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" NBRV shares.
View NBRV analyst ratings or view top-rated stocks.

How have NBRV shares performed in 2023?

Nabriva Therapeutics' stock was trading at $1.89 at the start of the year. Since then, NBRV shares have decreased by 22.8% and is now trading at $1.46.
View the best growth stocks for 2023 here.

When is Nabriva Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our NBRV earnings forecast.

How were Nabriva Therapeutics' earnings last quarter?

Nabriva Therapeutics plc (NASDAQ:NBRV) issued its quarterly earnings results on Monday, April, 17th. The biotechnology company reported ($7.77) earnings per share for the quarter. The biotechnology company had revenue of $10.57 million for the quarter. Nabriva Therapeutics had a negative trailing twelve-month return on equity of 365.53% and a negative net margin of 148.11%.

When did Nabriva Therapeutics' stock split?

Nabriva Therapeutics's stock reverse split on Friday, September 16th 2022. The 1-25 reverse split was announced on Friday, September 16th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Nabriva Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Acasti Pharma (ACST), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Heat Biologics (HTBX).

What is Nabriva Therapeutics' stock symbol?

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

How do I buy shares of Nabriva Therapeutics?

Shares of NBRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nabriva Therapeutics' stock price today?

One share of NBRV stock can currently be purchased for approximately $1.46.

How much money does Nabriva Therapeutics make?

Nabriva Therapeutics (NASDAQ:NBRV) has a market capitalization of $46.74 million and generates $35.59 million in revenue each year. The biotechnology company earns $-57,190,000.00 in net income (profit) each year or ($19.20) on an earnings per share basis.

How can I contact Nabriva Therapeutics?

Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406. The official website for the company is www.nabriva.com. The biotechnology company can be reached via phone at (531) 649-2000, via email at david.garrett@nabriva.com, or via fax at 610-816-6639.

This page (NASDAQ:NBRV) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -